Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

4.75USD
14 Dec 2017
Change (% chg)

$0.06 (+1.28%)
Prev Close
$4.69
Open
$4.70
Day's High
$5.15
Day's Low
$4.66
Volume
172,158
Avg. Vol
84,965
52-wk High
$11.79
52-wk Low
$3.30

Chart for

About

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase... (more)

Overall

Beta: --
Market Cap(Mil.): $181.90
Shares Outstanding(Mil.): 29.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Ocular Therapeutix posts Q3 loss per share $0.54

* Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

BRIEF-Ocular Therapeutix appoints Donald Notman as chief financial officer

* Ocular Therapeutix appoints Donald Notman as chief financial officer

25 Sep 2017

BRIEF-Ocular Therapeutix Q2 loss per share $0.64

* Ocular therapeutix™ reports second quarter 2017 financial results and provides corporate update

08 Aug 2017

BRIEF-Ocular hires Daniel Bollag for pharmacovigilance and quality

* Ocular Therapeutix appoints Daniel Bollag, PH.D., as senior vice president, regulatory affairs, pharmacovigilance and quality Source text for Eikon: Further company coverage:

03 Aug 2017

BRIEF-Ocular Therapeutix to eliminate 26 positions across organization

* Ocular Therapeutix says on july 31, board of directors approved a strategic restructuring to eliminate a portion of company's workforce - sec filing

01 Aug 2017

BRIEF-Ocular Therapeutix submits amendment to potentially extend review for Dextenza NDA

* Ocular Therapeutix submits amendment to potentially extend review for Dextenza New Drug Application (NDA)

10 Jul 2017

BRIEF-Ocular Therapeutix announces executive transition plans

* Says Antony Mattessich to assume CEO role in September 2017

22 Jun 2017

Earnings vs. Estimates